How low can your cholesterol go? Updates on cholesterol management beyond statins
Cardiovascular disease remains a primary cause of death among adults in the United States. Morbidity and mortality associated with cardiovascular disease can be largely attributed to the development of atherosclerotic cardiovascular disease including coronary disease, myocardial infarction, ischemic stroke, and peripheral arterial disease. Management of LDL and cholesterol has been proven to reduce risk of developing cardiovascular disease. New guidelines have been released in November of 2018 from the ACC/AHA and other organizations updating their recommendations in these patients. New PCSK9 inhibitors are mentioned in the guidelines but more information has come out since the guidelines were released. This presentation will update audience on the most up to date information regarding cholesterol management.
- Pharmacy technicians
- Identify updated recommendations made in the 2018 ACC/AHA guidelines on management of cholesterol
- Identify appropriate labs and monitoring for patients on pharmacological therapy for hyperlipidemia
- Discuss PCSK9 inhibitors and their place in therapy for the treatment of hyperlipidemia
- Describe the epidemiology and complications associated with hypercholesterolemia
- Identify brand/generic names of the pharmacological options for management of hyperlipidemia
- Identify appropriate administration and dosage forms of pharmacological options for management of hyperlipidemia
Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CEU – Attendance